As of Feb 12
| +0.019 / +5.94%|
The 3 analysts offering 12-month price forecasts for CTi Biopharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.70. The median estimate represents a +121.17% increase from the last price of 0.34.
The current consensus among 3 polled investment analysts is to Hold stock in CTi Biopharma Corp. This rating has held steady since February, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.